OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye DiseaseGlobeNewsWire • 09/08/23
OKYO Pharma dry eye disease trial reaches enrollment milestone; topline data expected by year-endProactive Investors • 08/30/23
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)GlobeNewsWire • 08/30/23
OKYO Pharma makes good progress with flagship OK-101 drug as it wraps up its 2023 financial yearProactive Investors • 08/15/23
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023GlobeNewsWire • 08/15/23
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical CenterGlobeNewsWire • 07/28/23
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating OfficerGlobeNewsWire • 07/27/23
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye DiseaseGlobeNewsWire • 06/06/23
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023GlobeNewsWire • 05/03/23
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye DiseaseGlobeNewsWire • 05/02/23
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye DiseaseGlobeNewsWire • 04/25/23
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred PayAccesswire • 04/18/23